• Users Online: 356
  • Print this page
  • Email this page
CASE REPORT
Year : 2021  |  Volume : 5  |  Issue : 1  |  Page : 31-33

Postintravenous immunoglobulins posterior reversible encephalopathy syndrome in a patient with miller fisher variant of guillain–barre syndrome: A case report and literature review


1 Department of Critical Care, Hamad General Hospital, Hamad Medical Corporation, Doha, Qatar
2 Department of Pharmacy, Alwakra Hospital, Hamad Medical Corporation, Doha, Qatar

Correspondence Address:
Dr. Ans Alamami
P.O. Box 3050, Al Rayan Street, Doha
Qatar
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/LJMS.LJMS_103_20

Rights and Permissions

Guillain–Barre syndrome (GBS) is an autoimmune disorder of the peripheral nerves manifested as inflammatory polyneuropathy of acute onset. The posterior reversible encephalopathy syndrome (PRES) is composed of gradual-onset neurological characteristics with unique radiological distribution (at the posterior brain region). Several etiologies, including hypertension, renal insufficiency, autoimmune diseases, medication use, and immunodeficiency, immunotherapy with intravenous immunoglobulin (IVIG) for various immune-related conditions, were associated with renal impairment, thrombotic manifestation, and reported PRES occurrence. Herein, we report a 73-year-old male who developed a clinical manifestation of PRES on top of IVIG therapy for Miller Fisher variant of GBS; therefore, PRES to be considered in a patient with GBS who treated with IVIG and developed alteration in the state of consciousness.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed254    
    Printed0    
    Emailed0    
    PDF Downloaded31    
    Comments [Add]    

Recommend this journal